With the recent FDA approval of neoadjuvant chemotherapy and nivolumab for Stage IB-IIIA NSCLC, does the fact that the study used AJCC 7th edition staging impact your patient selection at all since we currently are using 8th edition staging?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Wexner Medical Center at The Ohio State University
Answered on
No. The regimen is approved for all tumors greater than 4 cm OR node positive, and broad benefit was observed in all clinical categories.
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Cancer Care of Western Arizona
Answered on
No.
Join for free or sign in to see the full answer